Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Ogiya Akiko; Yamazaki Kieko; Horii Rie; Shien Tadahiko; Horimoto Yoshiya; Masuda Norikazu; Inao Touko; Hosoda Mitsuchika; Ishida Naoko; Osako Tomofumi; Takahashi Masato; Endo Yumi; Miyoshi Yuichiro; Yasojima Hiroyuki; Tomioka Nobumoto; Yamashita Hiroko; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

タイトル	en Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
作成者	en Ogiya, Akiko en Yamazaki, Kieko en Horii, Rie NRID 1000020446272 en Shien, Tadahiko NRID 1000030509451 en Horimoto, Yoshiya en Masuda, Norikazu en Inao, Touko en Hosoda, Mitsuchika NRID 1000040443931 en Ishida, Naoko en Osako, Tomofumi en Takahashi, Masato en Endo, Yumi NRID 1000020566228 en Miyoshi, Yuichiro en Yasojima, Hiroyuki en Tomioka, Nobumoto en Yamashita, Hiroko NRID 1000070332947 en Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society
アクセス権	open access
権利情報	en The final publication is available at link.springer.com
主題	Other en Breast cancer Other en Post-relapse survival Other en Prognosis Other en Estrogen receptor-positive Other en Endocrine therapy NDC 490
内容注記	Abstract en Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
出版者	en Springer
日付	Issued2017-05
言語	eng
資源タイプ	journal article
出版タイプ	AM
資源識別子	HDL http://hdl.handle.net/2115/70047
関連	isVersionOf DOI https://doi.org/10.1007/s12282-016-0730-3 PMID 27628678
収録誌情報	PISSN 1340-6868 en Breast cancer 巻24 号3 開始ページ473 終了ページ482
ファイル	fulltext BreastCancer24_473.pdf 257.03 KB (application/pdf) Issued2017-05
コンテンツ更新日時	2023-07-26